A straightforward online process backed by licensed clinical and pharmacy partners
For decades, this trend seemed to be insurmountable contributing to an obesity pandemic that places an enormous burden on our collective health due to obesitys association with various conditions including type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD), and certain types of cancer to name just a few [2]
Statistical significance was analyzed by two-way repeated measures ANOVA
One notable finding from meta-analyses: cagrilintide demonstrated the lowest odds ratios for nausea, vomiting, and diarrhea when compared to other incretin-based therapies including semaglutide and tirzepatide
The 98 Percent Problem Susan Sweeney, executive vice president of obesity and related conditions at Amgen, introduced the conversation between Stephens and Kyle with a staggering statistic: Only about two percent of people with obesity are receiving treatment currently
